Each year the J.P. Morgan Healthcare Conference serves as the start of medtech’s season. Now that it has ended, here are 7 key things we learned about companies presenting during the event.
The San Clemente, CA-based firm is developing several glaucoma treatment products as it transitions into a hybrid surgical, pharmaceutical, and medical device company.
The San Diego-based company presented at the 37th annual J.P. Morgan Healthcare Conference and said its revenue increased by 43% in 2018 despite mounting competition from rivals.
The Boulder, CO-based company has been granted a Breakthrough Device Designation for its liquid biopsy and tissue specimen assay.
The San Francisco-based company and developer of the Zio Patch is set to present at the 37th Annual J.P. Morgan Healthcare Conference this week.
The Irvine, CA-based company said it was limiting the device to only be available for use under clinical protocol with pre-screened patients that adhere to the current indications.
Google’s former life sciences division said it would use the proceeds from the $1 billion investment round to help with its collaborations and potential acquisitions.
The two companies will look at advancing the development and commercialization of diagnostic tests for early detection of the disease.
In 2014, renal denervation procedures to treat resistant hypertension took a crippling blow, when Medtronic failed to meet the primary endpoints in a trial, but recent activity from the Dublin-based firm and others indicates that the space is hot once again.
FDA’s nod for the Sapien 3 Ultra valve comes at a time when the TAVR market is heating up with competition.
The obesity treatment market has been through some changes lately and Obalon’s new funding deals could help the company navigate through some of these shifts and keep competitors at bay.
The Marlborough, MA-based company strengthens its structural heart portfolio and gains a deeper foothold in a market where Medtronic, Abbott Laboratories, and Edwards Lifesciences have already made significant acquisitions.